Shots:
- ProQR is eligible to receive ~$115M up front and milestone along with royalties on the sales of any resulting products during the royalty term and gets the right to receive a percentage of equity in the form of Yarrow shares
- Yarrow has in-licensed exclusive rights for ProQR’s ASO technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target
- ProQR will responsible for preclinical activities with reimbursement for the research costs, while Yarrow will lead the development of the program and commercialization activities
Click here to read full press release/ article | Ref: GLOBE NEWSWIRE | Image: ProQR
The post ProQR Therapeutics Signs an Exclusive Worldwide License Agreement with Yarrow to Develop Therapies for Non-Ophthalmic Target first appeared on PharmaShots.
